Companies / Israel
Teva Posts Record Results, But Risks Grow
November 2006 | Industry NewsIsraeli generic giant Teva has recorded a 127% increase in profit in Q306, to US$606mn, with sales reaching US$2.29bn, up 74%. However, despite the stellar performance, BMI cautions that the company may face difficult times
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
